We are delighted to announce that Lucence has achieved a perfect score for our BRCA genetic tests in external quality assessment by the European Molecular Genetics Quality Network (EMQN). This excellent result affirms our accurate and reliable laboratory genetic testing.
EMQN provides proficiency testing schemes, which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data based on the clinical information provided, and to produce a clear and accurate report.
In addition to our specialized sequencing, our genetic tests also include multiplex ligation-dependent probe amplification (MLPA) screening. MLPA allows us to detect large genomic rearrangements in BRCA genes, which contribute to 10-20% of all BRCA genetic variants.
Lucence is committed to delivering high-quality genetic testing to our customers. We therefore participate in external quality assessments to ensure that our tests meet industry benchmarks. With this perfect score and our MLPA testing, our customers and patients can continue to be assured of the highest reliability and accuracy of our tests for making important healthcare decisions!